Alnylam Pharmaceuticals Announces Publication of Pre-clinical Results with ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington’s Disease, in Experimental Neurology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of promising pre-clinical results in Experimental Neurology (doi:10.1016/j.expneurol.2011.11.020) related to its ALN-HTT program, an RNAi therapeutic drug-device combination for the treatment of Huntington’s disease.